Published: Fri, 15 September 2023
Seán Kelly MEP for Ireland South, welcomes Japanese pharmaceutical company, Astellas’, announcement that the company will invest €330m in a cutting-edge drug manufacturing facility in Tralee, County Kerry.
“This announcement is a great boost for Kerry’s economy and the Southwest region more broadly, Astellas new facility will bring over a hundred highly skilled jobs to the area, in research, engineering and tech. This announcement is another example of increasing recognition internationally that the Kingdom is an attractive place to do business”, Kelly stated. Astellas already has significant operations in Killorglin in Kerry.
Kelly added, “In addition, I am particularly pleased with Astellas commitment to sustainability in their operations.”
The company has stated its intention for the new Tralee facility to use 50 % less water than its existing plants, reduce its energy use by more one-third, and produce zero waste to landfill.
“This commitment to environment responsibility, and a clear intention to bring their industrial practices in line with our national and European sustainability goals, is a commendable”.
Astellas operates over eight manufacturing facilities and sixteen R&D facilities globally, producing a range of drugs, addressing urological diseases, cancer, nephrology, infectious diseases, metabolic diseases, as well as addressing issues related to immunodeficiency and transplantation. The company hopes to begin construction on the new facility in the next year.